Abstract
Ammonia succinate potentiates the main pharmacological properties and reduces the toxic effects (ulcerogenic action and general toxicity) of acetylsalicylic acid. The new preparation astam, representing a combination of acetylsalicylic acid with ammonia succinate in a 2:1 ratio, is proposed. Astam exhibits antiexudative, capillary-reinforcing, antiproliferative, pain-relieving, antipyretic, antiaggregant, and antioxidant properties. In addition, the drug inhibits the development of structural-metabolic disorders in the case of chronic immune inflammation of joints and various internal organs.
MeSH terms
-
Animals
-
Anti-Inflammatory Agents, Non-Steroidal / pharmacology*
-
Anti-Inflammatory Agents, Non-Steroidal / therapeutic use
-
Anti-Inflammatory Agents, Non-Steroidal / toxicity
-
Antioxidants / pharmacology
-
Antioxidants / therapeutic use
-
Antioxidants / toxicity
-
Arthritis, Experimental / drug therapy
-
Arthritis, Experimental / metabolism
-
Aspirin / pharmacology*
-
Aspirin / therapeutic use
-
Aspirin / toxicity
-
Dose-Response Relationship, Drug
-
Drug Combinations
-
Female
-
Lethal Dose 50
-
Male
-
Mice
-
Peptic Ulcer / chemically induced
-
Platelet Aggregation Inhibitors / pharmacology
-
Platelet Aggregation Inhibitors / therapeutic use
-
Platelet Aggregation Inhibitors / toxicity
-
Rats
-
Succinic Acid / pharmacology*
-
Succinic Acid / therapeutic use
-
Succinic Acid / toxicity
-
Toxicity Tests, Acute
Substances
-
Anti-Inflammatory Agents, Non-Steroidal
-
Antioxidants
-
Drug Combinations
-
Platelet Aggregation Inhibitors
-
aspirin, succinic acid drug combination
-
Succinic Acid
-
Aspirin